B. Riley Forecasts Agenus’ FY2024 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at B. Riley decreased their FY2024 earnings per share estimates for shares of Agenus in a report released on Monday, November 18th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings of ($10.51) per share for the year, down from their previous estimate of ($6.27). B. Riley currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.93) per share. B. Riley also issued estimates for Agenus’ Q4 2024 earnings at ($1.56) EPS, Q1 2025 earnings at ($2.13) EPS, Q2 2025 earnings at ($0.56) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($2.07) EPS, FY2025 earnings at ($5.83) EPS, FY2026 earnings at ($8.68) EPS, FY2027 earnings at ($7.86) EPS and FY2028 earnings at ($2.20) EPS.

A number of other equities analysts have also issued reports on the stock. HC Wainwright dropped their target price on shares of Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 12th. StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Agenus Stock Up 7.1 %

Shares of AGEN stock opened at $2.86 on Wednesday. Agenus has a 12 month low of $2.50 and a 12 month high of $19.69. The firm has a market cap of $67.10 million, a PE ratio of -0.25 and a beta of 1.39. The stock has a 50 day moving average of $4.47 and a 200-day moving average of $8.42.

Institutional Investors Weigh In On Agenus

A number of institutional investors have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. lifted its position in shares of Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after buying an additional 4,134,232 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after acquiring an additional 720,629 shares during the period. Geode Capital Management LLC boosted its stake in shares of Agenus by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after purchasing an additional 32,016 shares in the last quarter. State Street Corp grew its holdings in shares of Agenus by 2.1% in the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 123,058 shares in the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.